2023-504324-26-00
Recruiting
Phase 1
Randomized, Double Blind, Placebo Controlled "first-in-human" Study to Assess the Safety and Tolerability of Single Ascending Intravenous Doses and Multiple Intravenous Doses of RA0127 in Healthy Young Volunteers
Remab Therapeutics S.L.1 site in 1 country40 target enrollmentStarted: June 12, 2023Last updated:
Overview
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Remab Therapeutics S.L.
- Enrollment
- 40
- Locations
- 1
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 64 years (18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Rafael Mañez Mendiluce
Scientific
Remab Therapeutics S.L.
Study Sites (1)
Loading locations...
Similar Trials
Active, not recruiting
Phase 1
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, 6-Week, Hospitalized Patients, Study to Assess Efficacy and Safety of HP-3070 in Subjects with SchizophreniaEUCTR2015-005134-21-SKoven Pharmaceuticals, Inc.617
Active, not recruiting
Not Applicable
A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1 to 23 Months of Age, Inclusive) With Refractory Partial-Onset Seizures, With Open-Label ExtensioAdjunct to Concurrent Anticonvulsant Therapy for Infants (1 to 23 Months of Age, Inclusive) With Refractory Partial-Onset SeizuresMedDRA version: 6.1Level: PTClassification code 10010145EUCTR2005-001338-33-ITJANSSEN-CILAG240
Active, not recruiting
Not Applicable
A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (50 µg/h, 100 µg/h, 150 µg/h) Given Intravenously to Subjects with Acute Decompensated Chronic Congestive Heart Failure (ADHF) within 12 hours after hospital admission (Pulmonary Artery Catheter eg, Swan-Ganz not required) - COMPOSE EARLYAcute Decompensated Chronic Congestive Heart Failure (ADHF)MedDRA version: 9.1Level: LLTClassification code 10064653Term: Acute decompensated heart failureEUCTR2009-017082-39-GBBayer Healthcare AG, D-51368, Leverkusen160
Active, not recruiting
Not Applicable
A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (50 µg/h, 100 µg/h, 150 µg/h) Given Intravenously to Subjects with Acute Decompensated Chronic Congestive Heart Failure (ADHF) within 12 hours after hospital admission (Pulmonary Artery Catheter eg, Swan-Ganz not required. - COMPOSE EARLYAcute Decompensated Chronic Congestive Heart Failure (ADHF)MedDRA version: 12.1Level: LLTClassification code 10064653Term: Acute decompensated heart failureEUCTR2009-017082-39-ITBayer HealthCare AG160
Active, not recruiting
Not Applicable
A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects with Acute Decompensated Chronic Congestive Heart Failure (ADHF)Acute Decompensated Chronic Congestive Heart Failure (ADHF)MedDRA version: 9.1Level: LLTClassification code 10064653Term: Acute decompensated heart failureEUCTR2009-014377-40-SEBayer Healthcare AG100